IP Library Granted Patent US 9,377,569
Granted Patent B2
US 9,377,569 · App. 12/731,215 · Granted Jun 28, 2016

Photochromic ophthalmic systems that selectively filter specific blue light wavelengths

Inventors: Andrew W. Ishak (Havre de Grace, MD); Joshua N. Haddock (Roanoke, VA); William Kokonaski (Gig Harbor, WA); Dwight P. Duston (Laguna Niguel, CA); Venkatramani S. Iyer (Roanoke, VA); Ronald D. Blum (Roanoke, VA); Sean P. McGinnis (Roanoke, VA); Michael B. Packard (Cincinnati, OH)
Assignee: High Performance Optics, Inc.
G02B5/23G02C7/102G02C2202/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,377,569
App. No.
12/731,215
Granted
Jun 28, 2016
Kind
B2
Abstract

Ophthalmic systems are provided that include both a photochromic component and a blue-blocking component.

Claims (41)

1. An ophthalmic system comprising:

a photochromic component with an activated state and an inactivated state; and

a blue-blocking component disposed anterior to the photochromic component,

wherein, with the photochromic component in the inactivated state or the activated state, the blue-blocking component filters a selected range of light that includes 430 nm and is within the range of 420 nm to 440 nm, and transmits light at each wavelength from 400 nm to 700 nm that is above the selected range with a transmission rate of at least 80%, and

wherein the photochromic component, in the activated state, filters visible light including wavelengths outside the selected range.

2. The ophthalmic system of claim 1 , wherein the average transmission across the visible spectrum in the activated state is at least 20% less than the average transmission across the visible spectrum in the inactivated state.

3. The ophthalmic system of claim 1 , wherein the average transmission of the selected range of blue light wavelengths in the activated state is less than the average transmission of the selected range of blue light wavelengths in the inactivated state.

4. The ophthalmic system of claim 1 , wherein the average transmission of the selected range of blue light wavelengths in the activated state is within 20% of the average transmission of the selected range of blue light wavelengths in the inactivated state.

5. The ophthalmic system of claim 4 , wherein the average transmission of the selected range of blue light wavelengths in the activated state is within 5% of the average transmission of the selected range of blue light wavelengths in the inactivated state.

6. The ophthalmic system of claim 1 , wherein the blue-blocking component is not photochromic.

7. The ophthalmic system of claim 1 , wherein the blue-blocking component selectively filters at least 20% of light in the selected range of blue light wavelengths.

8. The ophthalmic system of claim 7 , wherein the blue-blocking component selectively filters at least 50% of light in the selected range of blue light wavelengths.

9. The ophthalmic system of claim 1 , further comprising at least one additional blue-blocking component that selectively filters a selected range of wavelengths including a chromophore other than A2E.

10. The ophthalmic system of claim 1 , wherein the system increases contrast sensitivity by at least one point on a sine wave grating test.

11. The ophthalmic system of claim 1 , wherein in the inactivated state, the system has a yellowness index of less than 8.

12. The ophthalmic system of claim 1 , wherein in the inactivated state, the system has a yellowness index of less than 5.

13. The ophthalmic system of claim 1 , wherein white light has CIE (x,y) coordinates of (0.33±0.05, 0.33±0.05) when transmitted through the inactivated and/or activated state.

14. The ophthalmic system of claim 1 , wherein the blue-blocking component comprises at least one of perylene, porphyrin, coumarin, acridine, and derivatives thereof.

15. The ophthalmic system of claim 14 , wherein the blue-blocking component comprises perylene or a derivative thereof.

16. The ophthalmic system of claim 14 , wherein the blue-blocking component comprises porphyrin or a derivative thereof.

17. The ophthalmic system of claim 16 , wherein the blue-blocking component comprises magnesium tetramesitylporphyrin.

18. The ophthalmic system of claim 1 , wherein the blue-blocking component comprises a blue-blocking dye at a concentration of about 1 ppm to about 50 ppm.

19. The ophthalmic system of claim 18 , wherein the blue-blocking component comprises a blue-blocking dye at a concentration of about 2 ppm to about 10 ppm.

20. The ophthalmic system of claim 1 , wherein the photochromic component is activated by at least one of UVB, UVA, blue light, visible light, and infrared wavelengths.

21. The ophthalmic system of claim 20 , wherein the photochromic component is activated by at least one of UVB, UVA, and infrared wavelengths.

22. The ophthalmic system of claim 20 , wherein the photochromic component is activated by light having a wavelength of about 380 nm to about 410 nm.

23. The ophthalmic system of claim 1 , further comprising a UV filter.

24. The ophthalmic system of claim 23 , wherein the UV filter is positioned posterior to the photochromic component.

25. The ophthalmic system of claim 23 , wherein the UV filter does not filter the wavelengths that activate the photochromic component to a degree that prevents activation.

26. The ophthalmic system of claim 1 , wherein the system is an ophthalmic lens, spectacle lens, contact lens, intra-ocular lens, corneal inlay, corneal onlay, corneal graft, or electro-active lens.

27. The ophthalmic system of claim 26 , wherein at least one of the photochromic component and the blue-blocking component is present throughout the system.

28. The ophthalmic system of claim 1 , wherein the system is a spectacle lens.

29. The ophthalmic system of claim 1 , wherein at least one of the photochromic component and the blue-blocking component is localized in the system.

30. The ophthalmic system of claim 1 , wherein the blue-blocking component comprises a blue-blocking layer and/or the photochromic component comprises a photochromic layer.

31. The ophthalmic system of claim 1 , wherein the blue-blocking component is not in physical contact with the photochromic component.

32. The ophthalmic system of claim 1 , wherein in the inactivated state, the system has a yellowness index of no more than 15.

33. The ophthalmic system of claim 1 , wherein the blue-blocking component selectively filters at least 10% of light in the selected range of blue light wavelengths.

34. The ophthalmic system of claim 1 , wherein the blue-blocking component selectively filters at least 30% of light in the selected range of blue light wavelengths.

35. The ophthalmic system of claim 1 ,

wherein the blue-blocking component transmits light at each wavelength from 400 nm to 700 nm that is below the selected range with a transmission rate that is higher than the transmission rate of light at the wavelength within the selected range with the lowest transmission rate.

36. The ophthalmic system of claim 1 , wherein the blue-blocking component is an anti-reflective (AR) coating.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2010
From: ISHAK, ANDREW W.; HADDOCK, JOSHUA N.; KOKONASKI, WILLIAM; DUSTON, DWIGHT P.; IYER, VENKATRAMANI S.; BLUM, RONALD D.; MCGINNIS, SEAN P.; PACKARD, MICHAEL B.
To: HIGH PERFORMANCE OPTICS, INC.
Reel/Frame 024450/0347 →
Continuity (11)
Continuation In Part 11933069 · Oct 31, 2007
Continuation In Part 11761892 · Jun 12, 2007
Continuation In Part 11378317 · Mar 20, 2006
Continuation In Part 11892460 · Aug 23, 2007
Provisional Application 61163227 · Mar 25, 2009
Provisional Application 60812628 · Jun 12, 2006
Provisional Application 60836432 · Aug 23, 2006
Provisional Application 60841502 · Sep 1, 2006
Provisional Application 60861247 · Nov 28, 2006
Provisional Application 60978175 · Oct 8, 2007
Related Publication 20110075096A1 · Mar 31, 2011